NASDAQ: FHTX - Foghorn Therapeutics Inc.

Rentabilité sur six mois: +44.15%
Secteur: Healthcare

Calendrier des promotions Foghorn Therapeutics Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

Plus de détails
It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Выручка 0.00043
EBITDA -0.0499
Число акций ао 0.04197 млрд
P/S 1892.59
P/BV 5.57
EV/EBITDA -0.033
Цена ао 6.07
ISIN US3441741077
Сайт https://foghorntx.com
Валюта usd
IPO date 2020-10-23
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Changement de prix par jour: 0% (7.64)
Changement de prix par semaine: +5.23% (7.26)
Changement de prix par mois: -21.4% (9.72)
Changement de prix sur 3 mois: +26.49% (6.04)
Changement de prix sur six mois: +44.15% (5.3)
Changement de prix par an: +139.12% (3.195)
Evolution du prix sur 3 ans: -42.43% (13.27)
Evolution des prix depuis le début de l'année: +92.93% (3.96)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 8.16 1
P/BV -3.61 0
P/E 0 0
EV/EBITDA -2.45 0
Total: 3.88

Efficacité

Nom Signification Grade
ROA, % -34.42 0
ROE, % 127.51 10
Total: 3.33

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.4542 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 7843.02 10
Rentabilité Ebitda, % 98.89 9
Rentabilité EPS, % 0.2094 1
Total: 7.8
Plus de détails

Date de transaction Date de divulgation Insider Taper Prix Volume Quantité Partagez jusqu'à, % Partager après, % Document
23.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Vente 10.17 8 716 857 0 0 lien
23.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Achat 3.72 3 188 857 0 0 lien
20.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Vente 10.04 358 990 35756 0 -0.09 lien
20.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Achat 3.72 133 012 35756 0 0.09 lien
18.09.2024 20.09.2024 Costa Carlos
Chief People Officer		 Vente 10.05 116 319 11574 0 -0.03 lien
18.09.2024 20.09.2024 Costa Carlos
Chief People Officer		 Achat 3.72 43 055 11574 0 0.03 lien

Établissements Volume Partager, %
Flagship Pioneering Inc. 12674120 29.78
FMR, LLC 2810009 6.6
Raymond James & Associates, Inc. 2068387 4.86
Euclidean Capital LLC 1573761 3.7
Blackrock Inc. 1305868 3.07
Vanguard Group Inc 1025113 2.41
Artal Group S.A. 720720 1.69
Point72 Asset Management, L.P. 540000 1.27
Alphabet Inc. 500901 1.18
Geode Capital Management, LLC 448350 1.05

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
Avantis U.S. Equity ETF 0.0004 32.224830464267 1.59151
Range Cancer Therapeutics ETF 2.15956 47.24446537918 0.11955
ProShares Hedge Replication ETF 0.00149 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.06408 36.318555985322 1.54048
iShares Russell 2000 Growth ETF 0.01111 38.042556988 0.6026
ProShares UltraPro Russell2000 0.00545 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.01 39.350070246167 0.60264
Vanguard Russell 2000 ETF 0.01 35.648084105685 1.48801



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Adrian H. B. Gottschalk President, CEO & Director 784.65k 1976 (48 années)
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer 572.6k 1965 (59 années)
Mr. Michael J. LaCascia Chief Legal Officer 565.5k 1965 (59 années)
Dr. Gerald R. Crabtree M.d. Founder & Member of Scientific Advisory Board N/A
Mr. Saurabh Sewak Ph.D. Vice President of Corporate Development N/A
Mr. Carlos Costa Chief People Officer N/A 1973 (51 année)
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer 300.16k 1971 (53 année)
Ms. Karin Hellsvik VP of Corporate Affairs & Investor Relations N/A
Mr. Kristian Humer M.B.A. Chief Financial Officer N/A 1976 (48 années)
Dr. Anna Rivkin Ph.D. Chief Business Officer

Adresse: United States, Cambridge. MA, 500 Technology Square - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://foghorntx.com